Recent findings from a multi-state study reveal that the RSV vaccine is approximately 80% effective in preventing severe ...

Respiratory syncytial virus, or RSV, typically presents as mild, with symptoms similar to the common cold for adults and ...

Experts share the official predictions for RSV surge levels in 2024 and 2025, why the levels change each year, and how to ...

Respiratory season is among us, and Respiratory Syncytial Virus immunizations are now available for older adults and pregnant ...

The CDC’s vaccine advisors on Thursday maintained that respiratory syncytial virus immunization is only recommended for ...

Sanofi and CD&R entered into exclusive negotiations for the potential sale and purchase of a 50% controlling stake in Opella.

Arexvy is currently approved for active immunization for the prevention of LRTD caused by RSV in individuals 60 years of age and older, and those 50 to 59 years of age who are at increased risk for ...

The CDC's vaccine policy advisors haven't budged on new RSV guidance, remaining unconvinced that younger adults at higher ...

GSK unveils new Arexvy data showing strong protection in adults 18-49 at risk for RSV. The vaccine could broaden coverage for ...

GSK (GSK) reported its RSV vaccine Arexvy elicited a robust immune response in people aged 18 to 49 years who were at ...

“These promising data add to the evidence supporting GSK’s RSV vaccine and could help expand protection to more adults at ...

FDA has approved Abrysvo for active immunization for the prevention of lower respiratory tract disease caused by RSV.